Oncotarget

Research Papers:

Compound genetically engineered mouse models of cancer reveal dual targeting of ALK1 and endoglin as a synergistic opportunity to impinge on angiogenic TGF-β signaling

Nikolas M. Eleftheriou, Jonas Sjölund, Matteo Bocci, Eliane Cortez, Se-Jin Lee, Sara I. Cunha and Kristian Pietras _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:84314-84325. https://doi.org/10.18632/oncotarget.12604

Metrics: PDF 1414 views  |   HTML 2391 views  |   ?  


Abstract

Nikolas M. Eleftheriou1, Jonas Sjölund1, Matteo Bocci1, Eliane Cortez1, Se-Jin Lee2, Sara I. Cunha3,*, Kristian Pietras1,*

1Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Medicon Village, Lund, Sweden

2Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD, USA

3Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

*These authors contributed equally to this work

Correspondence to:

Sara I. Cunha, email: Sara.Cunha@igp.uu.se

Kristian Pietras, email: Kristian.Pietras@med.lu.se

Keywords: angiogenesis, targeted therapy, BMP9, ALK1, endoglin

Received: June 04, 2016     Accepted: October 03, 2016     Published: October 12, 2016

ABSTRACT

Angiogenesis occurs early in tumor development, sustains primary tumor growth and provides a route for metastatic escape. The TGF-β family receptors modulate angiogenesis via endothelial-cell specific pathways. Here we investigate the interaction of two such receptors, ALK1 and endoglin, in pancreatic neuroendocrine tumors (PanNET). Independently, ALK1 and endoglin deficiencies exhibited genetically divergent phenotypes, while both highly correlate to an endothelial metagene in human and mouse PanNETs. A concurrent deficiency of both receptors synergistically decreased tumor burden to a greater extent than either individual knockdown. Furthermore, the knockout of Gdf2 (BMP9), the primary ligand for ALK1 and endoglin, exhibited a mixed phenotype from each of ALK1 and endoglin deficiencies; overall primary tumor burden decreased, but hepatic metastases increased. Tumors lacking BMP9 display a hyperbranching vasculature, and an increase in vascular mesenchymal-marker expression, which may be implicit in the increase in metastases. Taken together, our work cautions against singular blockade of BMP9 and instead demonstrates the utility of dual blockade of ALK1 and endoglin as a strategy for anti-angiogenic therapy in PanNET.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12604